Biotechnology Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 – Ocugen (NASDAQ:OCGN) Read more
Biotechnology GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom – GRI Bio (NASDAQ:GRI) Read more
Biotechnology Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis – Enlivex Therapeutics (NASDAQ:ENLV) Read more